Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation.

DeFilipp Z, Li S, Avigan D, Armand P, Ho VT, Koreth J, Nikiforow S, Alyea EP, Ritz J, Boussiotis V, Rosenblatt J, Brown J, McAfee S, Dey BR, El-Jawahri A, Spitzer TR, Chen YB, Soiffer RJ, Antin JH, Ballen KK, Cutler CS.

Bone Marrow Transplant. 2019 Oct 15. doi: 10.1038/s41409-019-0715-x. [Epub ahead of print]

PMID:
31616065
2.

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation.

Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen KK, Ritz J, Politikos I, Boussiotis VA.

Bone Marrow Transplant. 2019 Oct 2. doi: 10.1038/s41409-019-0707-x. [Epub ahead of print] No abstract available.

PMID:
31578466
3.

Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells.

Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen K, Marty FM, Tan CS, Ritz J, Politikos I, Boussiotis V.

Clin Immunol. 2019 Oct;207:18-23. doi: 10.1016/j.clim.2019.06.010. Epub 2019 Jun 27.

PMID:
31255803
4.

Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.

Tijaro-Ovalle NM, Karantanos T, Wang HT, Boussiotis VA.

Front Immunol. 2019 Mar 5;10:295. doi: 10.3389/fimmu.2019.00295. eCollection 2019. Review.

5.

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.

Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF 3rd, Hua P, Pham HC, Bu X, Zhu B, Hacohen N, Fritsch EF, Boussiotis VA, Wu CJ, Freeman GJ.

Cancer Immunol Immunother. 2019 Mar;68(3):421-432. doi: 10.1007/s00262-018-2282-1. Epub 2018 Dec 18.

6.

Unraveling Key Players of Humoral Immunity: Advanced and Optimized Lymphocyte Isolation Protocol from Murine Peyer's Patches.

Yazicioglu YF, Aksoylar HI, Pal R, Patsoukis N, Boussiotis VA.

J Vis Exp. 2018 Nov 21;(141). doi: 10.3791/58490.

PMID:
30531720
7.

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy.

Le Bourgeois T, Strauss L, Aksoylar HI, Daneshmandi S, Seth P, Patsoukis N, Boussiotis VA.

Front Oncol. 2018 Aug 3;8:237. doi: 10.3389/fonc.2018.00237. eCollection 2018. Review.

8.

Considerations on human Herpesvirus 6 reactivation after cord blood transplantation.

Phan T, Zerr DM, Boussiotis V, Lusso P, Di Luca D.

Am J Hematol. 2018 Sep;93(9):E249-E250. doi: 10.1002/ajh.25207. Epub 2018 Jul 30. No abstract available.

9.

Publisher Correction: Feeling stressed? It might be your T cells.

Strauss L, Patsoukis N, Boussiotis VA.

Nat Immunol. 2018 Sep;19(9):1037. doi: 10.1038/s41590-018-0140-0.

PMID:
29955108
10.

Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.

Politikos I, McMasters M, Bryke C, Avigan D, Boussiotis VA.

Blood Adv. 2018 Jun 26;2(12):1367-1370. doi: 10.1182/bloodadvances.2018015982. No abstract available.

11.

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Phan TL, Carlin K, Ljungman P, Politikos I, Boussiotis V, Boeckh M, Shaffer ML, Zerr DM.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2324-2336. doi: 10.1016/j.bbmt.2018.04.021. Epub 2018 Apr 21.

12.

Immunotherapies for malignant glioma.

Boussiotis VA, Charest A.

Oncogene. 2018 Mar;37(9):1121-1141. doi: 10.1038/s41388-017-0024-z. Epub 2017 Dec 15. Review.

13.

Feeling stressed? It might be your T cells.

Strauss L, Patsoukis N, Boussiotis VA.

Nat Immunol. 2017 Nov 16;18(12):1281-1283. doi: 10.1038/ni.3872. No abstract available. Erratum in: Nat Immunol. 2018 Sep;19(9):1037.

PMID:
29144505
14.

JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function.

Karantanos T, Boussiotis VA.

Transl Cancer Res. 2016 Nov;5(Suppl 6):S1208-S1211. doi: 10.21037/tcr.2016.11.11. No abstract available.

15.

The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression.

Patsoukis N, Bardhan K, Weaver JD, Sari D, Torres-Gomez A, Li L, Strauss L, Lafuente EM, Boussiotis VA.

Sci Signal. 2017 Aug 22;10(493). pii: eaam8298. doi: 10.1126/scisignal.aam8298. Review.

PMID:
28831022
16.

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Karantanos T, Politikos I, Boussiotis VA.

Blood Lymphat Cancer. 2017;7:37-52. doi: 10.2147/BLCTT.S105458. Epub 2017 May 9.

17.

Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.

Patsoukis N, Weaver JD, Strauss L, Herbel C, Seth P, Boussiotis VA.

Front Immunol. 2017 Apr 11;8:330. doi: 10.3389/fimmu.2017.00330. eCollection 2017. Review.

18.

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.

Bardhan K, Anagnostou T, Boussiotis VA.

Front Immunol. 2016 Dec 12;7:550. doi: 10.3389/fimmu.2016.00550. eCollection 2016. Review.

19.

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D.

Sci Transl Med. 2016 Dec 7;8(368):368ra171.

20.

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.

Boussiotis VA.

N Engl J Med. 2016 Nov 3;375(18):1767-1778. Review. No abstract available.

21.

Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

Christofides A, Karantanos T, Bardhan K, Boussiotis VA.

Oncotarget. 2016 Dec 20;7(51):85624-85640. doi: 10.18632/oncotarget.12928. Review.

22.

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.

Politikos I, T Kim H, Karantanos T, Brown J, McDonough S, Li L, Cutler C, Antin JH, Ballen KK, Ritz J, Boussiotis VA.

Biol Blood Marrow Transplant. 2017 Jan;23(1):103-112. doi: 10.1016/j.bbmt.2016.10.013. Epub 2016 Oct 21.

23.

Corrigendum: Regulation of T Cell Differentiation and Function by EZH2.

Karantanos T, Christofides A, Bardhan K, Li L, Boussiotis VA.

Front Immunol. 2016 Sep 14;7:346. doi: 10.3389/fimmu.2016.00346. eCollection 2016.

24.

Clinical significance of T cell metabolic reprogramming in cancer.

Herbel C, Patsoukis N, Bardhan K, Seth P, Weaver JD, Boussiotis VA.

Clin Transl Med. 2016 Dec;5(1):29. doi: 10.1186/s40169-016-0110-9. Epub 2016 Aug 10. Review.

25.

Regulation of T Cell Differentiation and Function by EZH2.

Karantanos T, Chistofides A, Barhdan K, Li L, Boussiotis VA.

Front Immunol. 2016 May 3;7:172. doi: 10.3389/fimmu.2016.00172. eCollection 2016. Review. Erratum in: Front Immunol. 2016;7:346.

26.

The role of metabolic reprogramming in T cell fate and function.

Patsoukis N, Bardhan K, Weaver J, Herbel C, Seth P, Li L, Boussiotis VA.

Curr Trends Immunol. 2016;17:1-12.

27.

Cell-specific PD-L1 expression in DLBCL.

Boussiotis VA.

Blood. 2015 Nov 5;126(19):2171-2. doi: 10.1182/blood-2015-08-663997. No abstract available.

PMID:
26542250
28.

IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults.

Politikos I, Kim HT, Nikiforow S, Li L, Brown J, Antin JH, Cutler C, Ballen K, Ritz J, Boussiotis VA.

PLoS One. 2015 Jul 15;10(7):e0132564. doi: 10.1371/journal.pone.0132564. eCollection 2015.

29.

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.

Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, Karoly ED, Freeman GJ, Petkova V, Seth P, Li L, Boussiotis VA.

Nat Commun. 2015 Mar 26;6:6692. doi: 10.1038/ncomms7692.

30.

BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation.

Satyanarayana G, Hammond SP, Broge TA Jr, Mackenzie MR, Viscidi R, Politikos I, Koralnik IJ, Cutler CS, Ballen K, Boussiotis V, Marty FM, Tan CS.

Transpl Immunol. 2015 Mar;32(2):116-20. doi: 10.1016/j.trim.2014.12.002. Epub 2014 Dec 20.

31.

Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma.

Boussiotis VA.

N Engl J Med. 2014 Dec 4;371(23):2230-2. doi: 10.1056/NEJMe1413061. Epub 2014 Nov 19. No abstract available.

32.

The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation.

Politikos I, Boussiotis VA.

Blood. 2014 Nov 20;124(22):3201-11. doi: 10.1182/blood-2014-07-589176. Epub 2014 Oct 6. Review.

33.

Biochemical signaling of PD-1 on T cells and its functional implications.

Boussiotis VA, Chatterjee P, Li L.

Cancer J. 2014 Jul-Aug;20(4):265-71. doi: 10.1097/PPO.0000000000000059. Review.

34.

The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.

Nellore A, Liu B, Patsoukis N, Boussiotis VA, Li L.

Clin Immunol. 2014 May-Jun;152(1-2):48-57. doi: 10.1016/j.clim.2014.02.015. Epub 2014 Mar 12.

35.

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT.

Li L, Kim HT, Nellore A, Patsoukis N, Petkova V, McDonough S, Politikos I, Nikiforow S, Soiffer R, Antin JH, Ballen K, Cutler C, Ritz J, Boussiotis VA.

Blood Cancer J. 2014 Jan 17;4:e178. doi: 10.1038/bcj.2013.75.

36.

The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer.

Li L, Boussiotis VA.

Clin Immunol. 2013 Aug;148(2):246-53. doi: 10.1016/j.clim.2013.05.003. Epub 2013 May 15. Review.

37.

PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.

Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA.

Mol Cell Biol. 2013 Aug;33(16):3091-8. doi: 10.1128/MCB.00319-13. Epub 2013 Jun 3.

38.

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D.

Clin Cancer Res. 2013 Jul 1;19(13):3640-8. doi: 10.1158/1078-0432.CCR-13-0282. Epub 2013 May 17.

39.

RIAM (Rap1-interacting adaptor molecule) regulates complement-dependent phagocytosis.

Medraño-Fernandez I, Reyes R, Olazabal I, Rodriguez E, Sanchez-Madrid F, Boussiotis VA, Reche PA, Cabañas C, Lafuente EM.

Cell Mol Life Sci. 2013 Jul;70(13):2395-410. doi: 10.1007/s00018-013-1268-6. Epub 2013 Feb 19.

40.

Rap1-interacting adapter molecule (RIAM) associates with the plasma membrane via a proximity detector.

Wynne JP, Wu J, Su W, Mor A, Patsoukis N, Boussiotis VA, Hubbard SR, Philips MR.

J Cell Biol. 2012 Oct 15;199(2):317-30. doi: 10.1083/jcb.201201157. Epub 2012 Oct 8.

41.

PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Patsoukis N, Sari D, Boussiotis VA.

Cell Cycle. 2012 Dec 1;11(23):4305-9. doi: 10.4161/cc.22135. Epub 2012 Oct 3.

42.

Runx1 and Runx3 are involved in the generation and function of highly suppressive IL-17-producing T regulatory cells.

Li L, Patsoukis N, Petkova V, Boussiotis VA.

PLoS One. 2012;7(9):e45115. doi: 10.1371/journal.pone.0045115. Epub 2012 Sep 12.

43.

Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.

Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1851-8. doi: 10.1016/j.bbmt.2012.06.016. Epub 2012 Jul 2.

44.

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA.

Sci Signal. 2012 Jun 26;5(230):ra46. doi: 10.1126/scisignal.2002796.

45.

Molecular and functional heterogeneity of T regulatory cells.

Li L, Boussiotis VA.

Clin Immunol. 2011 Dec;141(3):244-52. doi: 10.1016/j.clim.2011.08.011. Epub 2011 Aug 30. Review.

46.

Rap1-GTP-interacting adaptor molecule (RIAM) protein controls invasion and growth of melanoma cells.

Hernández-Varas P, Coló GP, Bartolomé RA, Paterson A, Medraño-Fernández I, Arellano-Sánchez N, Cabañas C, Sánchez-Mateos P, Lafuente EM, Boussiotis VA, Strömblad S, Teixidó J.

J Biol Chem. 2011 May 27;286(21):18492-504. doi: 10.1074/jbc.M110.189811. Epub 2011 Mar 26.

47.

Rap1A regulates generation of T regulatory cells via LFA-1-dependent and LFA-1-independent mechanisms.

Li L, Kim Js, Boussiotis VA.

Cell Immunol. 2010;266(1):7-13. doi: 10.1016/j.cellimm.2010.08.014. Epub 2010 Sep 22.

48.

IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells.

Li L, Kim J, Boussiotis VA.

J Immunol. 2010 Oct 1;185(7):4148-53. doi: 10.4049/jimmunol.1001536. Epub 2010 Sep 3.

49.

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K.

Bone Marrow Transplant. 2011 May;46(5):659-67. doi: 10.1038/bmt.2010.192. Epub 2010 Aug 9.

50.

Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28.

Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D.

J Immunother. 2010 Feb-Mar;33(2):155-66. doi: 10.1097/CJI.0b013e3181bed253.

Supplemental Content

Loading ...
Support Center